{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:41:38Z","timestamp":1763642498579,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.bbmt.2018.09.029","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T21:57:03Z","timestamp":1537999023000},"page":"321-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6502-6859","authenticated-orcid":false,"given":"Jeffrey R.","family":"Andolina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuko","family":"Hijiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9816-5126","authenticated-orcid":false,"given":"Sonali","family":"Chaudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirk R.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"1999","series-title":"Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program, 1975-1995","key":"10.1016\/j.bbmt.2018.09.029_bib0001"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0002","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0003","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0004","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0005","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/EDBK_175712","article-title":"Chronic myeloid leukemia: what every practitioner needs to know in 2017","volume":"37","author":"Khoury","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0006","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0007","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/pbc.23389","article-title":"Imatinib has adverse effect on growth in children with chronic myeloid leukemia","volume":"59","author":"Bansal","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0008","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/pbc.24121","article-title":"Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia","volume":"59","author":"Rastogi","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0009","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.bmt.1704255","article-title":"Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"32","author":"Millot","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0010","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood-2002-12-3637","article-title":"Stem cell transplantation for chronic myeloid leukemia in children","volume":"102","author":"Cwynarski","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0011","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbmt.2009.09.022","article-title":"Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program","volume":"16","author":"Muramatsu","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0012","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0029-1239529","article-title":"Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-PAED I","volume":"221","author":"Suttorp","year":"2009","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0013","doi-asserted-by":"crossref","unstructured":"Holmqvist AS, Chen Y, Wu J, et al. Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2 [e-pub ahead of print]. Leukemia. https:\/\/doi.org\/10.1038\/s41375-018-0171-4. Accessed July 20, 2018.","DOI":"10.1038\/s41375-018-0171-4"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0014","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2007-03-082933","article-title":"Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study","volume":"110","author":"Bhatia","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0015","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2016.02.015","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in children and young adults with chronic myeloid leukemia: a CIBMTR cohort analysis","volume":"22","author":"Chaudhury","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0016","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0017","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0018","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0019","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/pbc.24521","article-title":"Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase","volume":"61","author":"Millot","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0020","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/pbc.25090","article-title":"Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia","volume":"61","author":"Moser","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0021","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2011-10-380774","article-title":"How I treat childhood CML","volume":"119","author":"Andolina","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0022","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","article-title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","volume":"127","author":"Hijiya","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0023","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/ped.12876","article-title":"Optimal management for pediatric chronic myeloid leukemia","volume":"58","author":"Tanizawa","year":"2016","journal-title":"Pediatr Int"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0024","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pcl.2014.09.008","article-title":"Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions","volume":"62","author":"Hijiya","year":"2015","journal-title":"Pediatr Clin N Am"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11899-012-0113-6","article-title":"Management of chronic myeloid leukemia in childhood","volume":"7","author":"Suttorp","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0026","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood-2012-03-378919","article-title":"How I treat newly diagnosed chronic phase CML","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0027","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/pbc.22172","article-title":"The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era","volume":"53","author":"Burke","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0028","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.24249","article-title":"Chronic myeloid leukemia: first-line drug of choice","volume":"91","author":"Jabbour","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0029","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1080\/10428194.2017.1379074","article-title":"First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI","volume":"59","author":"Saglio","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0030","first-page":"S34","article-title":"Nilotinib in pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL): a pharmacokinetic study","volume":"64","author":"Hijiya","year":"2017","journal-title":"Pediatr Blood Cancer (Abstract)"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0031","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","article-title":"Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial","volume":"36","author":"Gore","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0032","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0033","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.09.029_bib0034","unstructured":"National Comprehensive Cancer Network. NCCN guidelines: chronic myeloid leukemia. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. Accessed September 9, 2018."},{"key":"10.1016\/j.bbmt.2018.09.029_bib0035","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118305962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118305962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:05:03Z","timestamp":1761059103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118305962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1083879118305962"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.029","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}